ClinicalTrials.gg
CompletedNCT02803762Updated Jun 17, 2016

Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

A Phase 1 interventional study of Pacritinib in Healthy, sponsored by CTI BioPharma. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-17.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study is an open-label, absorption, metabolism, excretion, and mass balance study of 400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose to 6 healthy male subjects following at least a 10-hour fast (not including water) on Day 1.

Read the detailed description

The present study is designed to investigate the absorption, metabolism, excretion as well as safety/tolerability of pacritinib following the administration of a single oral dose to healthy male volunteers. The pacritinib dose is administered with a [14C]-labeled form to enable detection and quantitation of dose-related material independent of possible biotransformation. The study design allows detection of potential human specific metabolites that have not been detected in the animal species. Subjects are confined at the clinical site from the time of Check-in until Day 14 post-dose, but may be discharged from the clinical site between Day 10 and 13 post-dose if study discharge criteria are met (i.e. completion of sufficient radioactivity excretion). All remaining subjects will be discharged from the clinical site on Day 14 post-dose irrespective of the study discharge criteria. The data obtained in this study will be used for the further clinical development of the compound.

02

Conditions studied

  • Healthy

Keywords

  • ADME
  • Pacritinib
03

In context

Lead sponsor

CTI BioPharma is the lead sponsor of 38 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking men between 18 and 55 years of age (inclusive)
  • within normal limits (according to the criteria used by QPS Netherlands BV including (less than or equal to 450 m/sec)
  • Normal vital signs measurements [defined as blood pressure (BP) between 90-140 mmHg systolic and 50-90 mmHg diastolic, resting heart rate (HR) between 40-100 beats/min, temperature (T) less than or equal to 37.6 degree C])
  • of 19.0-29.0 kg/m2 inclusive
  • Negative history of drug abuse or alcoholism within 1 year prior to Day 1
  • Negative tests on drug and alcohol screen at Screening and Check-in
  • Negative hepatitis panel including -surface antigen HBsAg], antibody [anti-HCV] and negative antibody (HIV)
  • No clinical laboratory value outside of the normal reference range unless deemed not by the Investigator in consultation with the Sponsor
  • Fertile male subjects and fertile female sexual partners of male subjects agree to use effective methods throughout the entire study. Female partners of must use highly effective methods (defined as those resulting in a failure rate of \<1% per year when used consistently and correctly). The contraceptive methods considered highly effective are intrauterine devices and hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release). Male subjects must use a condom with spermicide paste for the duration of the study and for 90 days after the EOS evaluation. When abstinence is used as a method of birth control, only true abstinence is acceptable, when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, ovulation, symptothermal, and post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Agreement to not donate sperm throughout the entire study and for 3 months after the end of the study
  • Willingness to comply with the protocol, including restrictions on diet, physical activity, and use of alcohol, medications, and other drugs during the study
  • Comprehend and willingness to sign an approved form for the study
  • At least one bowel movement a day

Exclusion criteria

Exclusion Criteria:

  • Participation in another radioactive clinical trial within the past 12 months
  • Actively participating in an experimental therapy study or who have received experimental therapy within 90 days of Day 1
  • Use of any other prescription medication within 21 days of Day 1, unless approved by Sponsor
  • Use of over-the-counter (OTC) medications or nonprescription preparations (including vitamins, minerals and phytotherapeutic/herbal/plant-derived preparations) that is known to induce drug-metabolizing enzymes, including CYP450 enzymes within the 7 days preceding Day 1 (except for spermicidal/barrier products and paracetamol)
  • Consumption of alcoholic beverages within 72 hours prior to Check-in (Day -1)
  • Consumption of grapefruit- and grapefruit-containing products within 7 days prior to Day 1
  • Consumption of xanthine containing beverages such as coffee, including energy drinks containing caffeine or tea within 2 days of Day 1
  • abnormal physical finding at Screening
  • Any severe acute or chronic medical condition, psychiatric condition, or laboratory abnormality that in the Investigator's opinion may increase the risk associated with study participation or administration of study treatment, or interfere with the interpretation of study results (such as gastrointestinal surgical history (except appendectomy), ileus or obstructive uropathy)
  • Diarrhea, nausea or vomiting within 7 days of Day 1
  • History of additional risk factors for torsade de pointes (TdP) (e.g. heart failure, hypokalemia defined as serum potassium \<3.0 mmol/L, family history of Long Syndrome)
  • Any illness during the 4 weeks prior to Day 1, unless deemed NCS by the Principal Investigator
  • Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens)
  • Known history or presence of food allergies or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
  • Any surgical procedures within 72 hours of Day 1
  • Blood draws of more than 400 mL during the conduct of any clinical study within 90 days prior to Day 1
  • Poor peripheral venous access
  • Donation of blood 30 days prior to Screening through end of study
  • Employment in a position that exposes the subject to radiation or requires that the subject's degree of radiation exposure be monitored (e.g. radiology technician)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Investigational: [14C] Pacritinib

    All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity).

    Drug: Pacritinib

Interventions

  • 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax)

    The PK parameters for \[14C\] pacritinib will be derived by non-compartmental analysis of the plasma concentration-time profiles and the PK parameters for the metabolites will be calculated, as deemed appropriate, based on the results of quantitative profiling performed on selected plasma and pooled urine samples from individual subjects

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose every 24 hours thereafter until Day 10, no later than Day 14

  2. The time to reach maximum plasma concentration (tmax)

    The PK parameters for \[14C\] pacritinib will be derived by non-compartmental analysis of the plasma concentration-time profiles and the PK parameters for the metabolites will be calculated, as deemed appropriate, based on the results of quantitative profiling performed on selected plasma and pooled urine samples from individual subjects

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose every 24 hours thereafter until Day 10, no later than Day 14

  3. The area under the plasma concentration-time curve from time zero to time of the last measured concentration above the limit of quantification (AUC0-t)

    The PK parameters for \[14C\] pacritinib will be derived by non-compartmental analysis of the plasma concentration-time profiles and the PK parameters for the metabolites will be calculated, as deemed appropriate, based on the results of quantitative profiling performed on selected plasma and pooled urine samples from individual subjects

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose every 24 hours thereafter until Day 10, no later than Day 14

  4. The area under the plasma concentration-time curve from time zero to 48 hours (AUC0- 48h)

    The PK parameters for \[14C\] pacritinib will be derived by non-compartmental analysis of the plasma concentration-time profiles and the PK parameters for the metabolites will be calculated, as deemed appropriate, based on the results of quantitative profiling performed on selected plasma and pooled urine samples from individual subjects

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose every 24 hours thereafter until Day 10, no later than Day 14

  5. The area under the plasma concentration-time curve from zero to infinity (AUC0-∞)

    0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose every 24 hours thereafter until Day 10, no later than Day 14

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose every 24 hours thereafter until Day 10, no later than Day 14

Secondary outcomes

  1. Treatment-emergent adverse events (AEs) and serious adverse events (SAEs), vital Signs, PE, clinical laboratory valuations, and ECGs

    Evaluate Safety and tolerability of a single oral dose of 400 mg \[14C\]pacritinib in healthy subjects

    Time frame: Day 1 through Day 42

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9713 GZ, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
Jun 17, 2016
Start
Jul 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Last update
Jun 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02803762
Lead sponsor
CTI BioPharma
Collaborators
QPS-Qualitix
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
Jul 2014
Primary completion
Oct 2014
Completion
Oct 2014
Last update
Jun 17, 2016

Study contacts

Khalid A Elaziz, MBBS, MD
principal investigator · QPS Netherlands BV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion